نتائج البحث - Mingshan Cheng

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndrome

    A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndrome حسب Chunting Ye, Hongyuan Yang, Mingshan Cheng, Leonard D. Shultz, Dale L. Greiner, Michael A. Brehm, James Keck

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Enhanced Charge Collection in MOF‐525–PEDOT Nanotube Composites Enable Highly Sensitive Biosensing

    Enhanced Charge Collection in MOF‐525–PEDOT Nanotube Composites Enable Highly Sensitive Biosensing حسب Tzu‐Yen Huang, Chung‐Wei Kung, Yu‐Te Liao, Sheng−Yuan Kao, Mingshan Cheng, Ting‐Hsiang Chang, Joel Henzie, Hatem R. Alamri, Zeid A. ALOthman, Yusuke Yamauchi, Kuo‐Chuan Ho, Kevin C.‐W. Wu

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy

    Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy حسب Minan Wang, Li‐Chin Yao, Mingshan Cheng, Danying Cai, Jan Martínek, Chong-xian Pan, Wei Shi, Ai‐Hong Ma, Ralph W. Vere White, Susan Airhart, Edison T. Liu, Jacques Banchereau, Michael A. Brehm, Dale L. Greiner, Leonard D. Shultz, Karolina Palucka, James Keck

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Modeling of Patient-Derived Xenografts in Colorectal Cancer

    Modeling of Patient-Derived Xenografts in Colorectal Cancer حسب Αναστασία Κατσιαμπούρα, Kanwal Raghav, Zhi-Qin Jiang, David G. Menter, Andreas Varkaris, Maria Pia Morelli, Shanequa Manuel, Ji Yuan Wu, Alexey V. Sorokin, Bahar Salimian Rizi, Christopher A. Bristow, Feng Tian, Susan Airhart, Mingshan Cheng, Bradley M. Broom, Jeffrey S. Morris, Michael J. Overman, Garth Powis, Scott Kopetz

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

    Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions حسب Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess, Jonathan P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, M. Raymond V. Finlay, Darren McKerrecher, Mingshan Cheng, Daniel P. Vang, Rebekah A. Burich, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: